Preoperative treatment of Hepatitis C is associated with lower prosthetic joint infection rates in US Veterans
Journal of Arthroplasty Mar 15, 2019
Bendich I, et al. – Via retrospective analysis of 2014-2018 data (n=42,628) from the US Department of Veterans Affairs, investigators assessed whether hepatitis C virus (HCV) is a modifiable risk factor in total joint arthroplasty (TJA) by comparing postoperative complications among patients with and without preoperative HCV treatment. They also determined lower prosthetic joint infection rates among US veterans. The investigators found that 6.0% of TJA patients had HCV, of whom 17.3% had received HCV treatment preoperatively. They noted lower implant infection rates at 90-days and 1-year postoperatively among treated HCV candidates vs untreated individuals. Among HCV-treated patients, odds ratios favored lower infection rates. They found lower rates of pneumonia and urinary tract infection in treated patients.
To read this article Sign up / Login for free
- Stay on top of policy changes & daily news that matter to you as a healthcare professional
- Update yourself with quick summaries from reputed journals in your specialty
- Earn from paid surveys and influence new developments in healthcare
- Participate in daily quizzes to improve skills and compete with peers
- Save yourself time, as we bring you these and more useful features all at one place!
You get a FREE lifetime membership, with a simple one-time sign up process!